DelSiTech

DelSiTech is a leading technology expert in the field of biodegradable silica controlled release for small molecule drugs, biologics, and viral vectors. The company collaborates with multiple pharmaceutical and biotechnology companies to develop and commercialize its proprietary drug delivery technology, transforming ideas into new drug products. DelSiTech is developing its own line of super generics/505(b)(2) products to address unmet medical and commercial needs. Its lead product, a long-acting hepatitis B antiviral, is set to enter clinical trials in 2019.